Terremoto Biosciences raised $108 million in a Series C to advance small-molecule medicines targeting AKT1, including a lead program for solid tumors defined by specific genetic alterations and a separate Phase 1 effort in hereditary hemorrhagic telangiectasia, where no approved therapies exist. The company says it will use the financing to support first-in-human development and expand its covalent drug discovery portfolio. The round includes investors such as RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines, with participation from existing backers including OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management. Terremoto’s founder and previous CEO background includes Mirati Therapeutics, acquired by Bristol Myers Squibb. The funding adds to the broader signal that investors remain willing to back differentiated small-molecule oncology programs when there is a clear translational biomarker or rare-disease path.